USPSTF: Don't Routinely Screen Pregnant Women for Bacterial Vaginosis
By News Staff
3/4/2008
The guidance related to pregnant women at high risk for preterm delivery is considered an "I" statement, meaning that the USPSTF has concluded "that the current evidence is insufficient to assess the balance of benefits and harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined." Again, the task force found no direct evidence indicating that screening for bacterial vaginosis reduces adverse health outcomes in these women; and evidence from good-quality studies on the benefits of treating the condition is conflicting.
The USPSTF found only poor evidence regarding potential harms of screening for bacterial vaginosis in either group of pregnant women; studies in this area were lacking. However, task force members found fair evidence that false-positive results from screening asymptomatic women at low risk for preterm delivery can lead to harms associated with treatment. They found conflicting evidence regarding the harms of treating the condition in asymptomatic women at high risk for preterm delivery.
According to the "Clinical Considerations" section of the USPSTF recommendation statement, specific risk factors for preterm delivery include "African-American race or ethnicity," low body mass index, vaginal bleeding, previous preterm delivery, pelvic infection and bacterial vaginosis. Bacterial vaginosis, the most common lower genital tract syndrome among women of reproductive age, is most frequently seen in black women, women of lower socioeconomic status and those who previously have delivered low-birthweight babies.
Studies have documented an association between bacterial vaginosis and preterm delivery, and it is this epidemiologic evidence that for years had been used as a rationale for screening asymptomatic pregnant women for the disease -- despite the fact that as many as half of all cases resolve spontaneously during pregnancy.
FDA Misses Target for Monitoring Antipsychotic Drug Use
ACIP Makes New Flu, Pneumococcal Vaccine Recommendations
NIH Consensus Development Conference to Address VBAC Issues
FDA Requires New Label Warnings for LABAs
NY, NJ Mumps Outbreak Affects More than 1,500
Study: Patients, Physicians Don't Always Agree on Key Health Concerns
Sanofi Shortens Shelf Life of Some H1N1 Vaccine Doses
Merck Resumes Distribution of Hib Vaccine
Lancet Retracts Controversial Study Linking MMR Vaccine, Autism
Download 2010 Shots Schedules for Smartphones, Handheld Devices
USPSTF Updates Screening Recs for Childhood, Teen Obesity
FPs' Training Critical to Haiti Disaster Response
Sibutramine Use Contraindicated in Patients With CVD, Says FDA
